Dainippon Sumitomo, Nitto Denko Join To Develop Schizophrenia Patch
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma and Nitto Denko have agreed to an alliance to develop a skin patch to deliver the former’s Lonasen (blonanserin) for treating schizophrenia.
You may also be interested in...
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.